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922Objective: Glutamate has been claimed to protect the heart from ischemia and to facilitate metabolic and he-
modynamic recovery after ischemia. The GLUTAmate for Metabolic Intervention in Coronary Surgery trial in-
vestigated whether an intravenous glutamate infusion given in association with surgery for acute coronary
syndrome could reduce mortality and prevent or mitigate myocardial injury and postoperative heart failure.
Methods: In the present prospective, triple-center, double-blind study, 861 patients undergoing surgery for acute
coronary syndrome were randomly assigned to an intravenous infusion of glutamate (n ¼ 428) or saline
(n ¼ 433) perioperatively.
Results: The incidence of the primary endpoint—a composite of 30-day mortality, perioperative myocardial in-
farction, and left ventricular heart failure at weaning from cardiopulmonary bypass—was 7.3% versus 5.8%
(P ¼ .41) in the glutamate and control groups, respectively. Patients with left ventricular failure at weaning
from cardiopulmonary bypass had a shorter median intensive care unit stay (25 vs 92 hours; P ¼ .02) if they
were treated with glutamate. In patients with unstable angina (Canadian Cardiovascular Society class IV) un-
dergoing isolated coronary artery bypass grafting (n¼ 458), the incidence of severe circulatory failure according
to the prespecified criteria was significantly lower in the glutamate group (1.3% vs 6.9%; P ¼ .004). On mul-
tivariate analysis, glutamate infusion was associated with a reduced risk of developing severe circulatory failure
(odds ratio, 0.17; 95% confidence interval, 0.04-0.72; P ¼ .02). A relative risk reduction exceeding 50% for
developing severe circulatory failure was seen in most risk groups undergoing isolated coronary artery bypass
grafting, with those with diabetes a notable exception.
Conclusions: The primary endpoint did not differ significantly between the groups. The secondary outcomes
and post hoc analyses warrant additional studies with regard to the potential beneficial effect of glutamate on
postischemic myocardial recovery. (J Thorac Cardiovasc Surg 2012;144:922-30)Supplemental material is available online.Adverse outcomes after coronary artery bypass grafting
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The Journal of Thoracic and Cardiovascular SurgGlutamate has been claimed to protect the heart from
ischemia and facilitate metabolic and hemodynamic
recovery after ischemic insults.4-7 The clinical usefulness
of glutamate has not been tested in randomized clinical
trials, although glutamate enhancement of cardioplegic
solutions has been advocated to protect the heart during
cardioplegic arrest.7 Intravenous infusion provides the
opportunity to supply the heart with substrate during the
preoperative and postoperative phases. With the latter
approach, encouraging results have been achieved in
high-risk CABG, in both study populations and clinical
practice.8-11 From this experience, the GLUTAmate for
Metabolic Intervention in Coronary Surgery
(GLUTAMICS) trial was initiated. The primary aim of
the present study was to test the hypothesis that
intravenous glutamate infusion given in association with
CABG for acute coronary syndrome can reduce mortality
and prevent or mitigate myocardial injury and
postoperative heart failure. The primary clinical trial
registration was 2003 Swedish Medical Product Agency
Dnr 151: 2003/70403, and the secondary registration was
ClinicalTrials.gov Identifier HUNCT00489827UH UR.ery c October 2012
Abbreviations and Acronyms
CABG ¼ coronary artery bypass graft
CCS ¼ Canadian Cardiovascular Society
CPB ¼ cardiopulmonary bypass
ICU ¼ intensive care unit
NSTEMI ¼ non–ST-segment elevation myocardial
infarction
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Patients
We recruited patients from October 4, 2005 to November 12, 2009 from
3 Swedish Cardiac Surgery Centers. The inclusion criteria were coronary
artery bypass surgery for acute coronary syndrome. Patients were consid-
ered for study inclusion if they were scheduled for emergent or urgent sur-
gery because of unstable angina, non–ST-segment elevation myocardial
infarction (NSTEMI) or unstable symptoms after ST-segment elevation
myocardial infarction. The patients were eligible for inclusion regardless
of whether the procedure was done on-pump or off-pump or if the patient
underwent a simultaneous valve procedure. Subgroup analyses were
planned for patients with increasing degrees of unstable angina. The exclu-
sion criteria were informed consent not possible because of a critical con-
dition or another reason, preoperative use of inotropic drugs or mechanical
circulatory assist, preoperative dialysis, redo procedure, unexpected intra-
operative findings or an event that increased themagnitude of the procedure
to overshadow the originally planned operation, age older than 85 years,
body weight greater than 125 kg, and food allergy known to have caused
flushing, a rash, or asthma.
Study Design
The GLUTAmate for Metabolic Intervention in Coronary Surgery trial
was an investigator-initiated, prospective, randomized, placebo-controlled,
double-blind trial with parallel assignment to glutamate or placebo (saline).
The trial was externally randomized in variable block sizes, and an external
professional statistician was provided with the randomization codes for in-
terim analysis. External monitoring and reporting of adverse events were
done according to the Good Clinical Practice standard.
The patients were randomly allocated to blinded intravenous infusion of
0.125 M L-glutamic acid solution (see the Appendix) or saline at a rate of
1.65 mL/kg of body weight per hour beginning at the induction of anesthe-
sia. The dosage of glutamate was determined from studies demonstrating
that an infusion rate of 30 to 40 mg glutamate/kg of body weight per
hour increased arterial whole blood levels by two- to threefold, sufficient
to meet the myocardial demands or to saturate the myocardial capacity
to extract glutamate from the circulation.12 Because the cardioplegia-
arrested heart has been reported to leak glutamate rather than to extract ex-
ogenous glutamate, the infusions were temporarily stopped during aortic
crossclamping.13 The infusions were resumed after declamping of the aorta
and continued for an additional 2 hours at this rate, after which the infusion
rate was halved and an additional 50 mL infused. The maximum volume
infused to any patient was 500 mL of study solution. The key study data
were prospectively recorded in a case report form (see the Appendix).
Endpoints
The primary endpoint was a composite of postoperative mortality (30
days), perioperative myocardial infarction, and left ventricular heart failure
in association with weaning from cardiopulmonary bypass (CPB) or after
completion of off-pump coronary artery bypass surgery. The primary end-
point was positive if 1 of the criteria was fulfilled.The Journal of Thoracic and CaThe secondary endpoints covered the postoperative hemodynamic state,
including the treatment and severity of postoperative heart failure, myocar-
dial ischemia and injury, renal function, and neurologic safety issues (see
the Appendix).
The main safety endpoints included postoperative mortality and
stroke. As an initial safety measure, S100 calcium binding protein B
(S-100B) was analyzed in cohort of 70 patients to detect potential sub-
clinical neurologic injury.14 The Swedish Medical Products Agency
requested surveillance and unblinding in cases of computed
tomography-verified stroke within 24 hours of surgery, mortality, and sus-
pected unexpected serious adverse reactions. Before unblinding was
done, the case was reviewed by the Clinical Endpoints Committee if sus-
pected circulatory problems had occurred.
All adverse events were registered and are reported in the Appendix. Ex-
ternal monitoring of all key data, adverse events, and unblinding proce-
dures was done by an independent professional monitoring team.
Clinical Endpoints Committee
Because of the lack of generally accepted criteria for postoperative heart
failure in association with cardiac surgery, a blinded Clinical Endpoints
Committee relying on prespecified criteria was considered necessary.15-17
All patients with suspected postoperative heart failure, as determined by
the mixed venous oxygen saturation and other hemodynamic data, the
use of inotropic drugs or mechanical circulatory support, an extended
intensive care unit (ICU) stay, and circulatory problems reported by
anesthesiologists or surgeons in the clinical database, were reviewed.
The committee also decided whether events leading to death were
cardiac in origin. The details are given in the Appendix.
Definitions
Postoperative mortality was defined as mortality within 30 days of sur-
gery. Hospital mortality was defined as mortality during the first hospital-
ization period, including the hospital stay at the referral hospital after
discharge from the cardiac surgical unit. A cardiac cause of death was as-
sessed by the Endpoints Committee.
Postoperative heart failure was categorized as heart failure evident at
weaning from CPB or late circulatory failure presenting after apparently
uncomplicated weaning. Late circulatory failure was classified as cardiac
or noncardiac in origin. Prespecified criteria (available in the Appendix)
were used to determine whether heart failure was present. Severe circula-
tory failure was defined as heart failure leading to death or requiring an
ICU stay of 48 hours or longer with intra-aortic balloon pump for 24 hours
or longer or inotropic agents in dosages according to the Appendix criteria
for 24 hours or longer.
Perioperative myocardial infarction was defined by prespecified criteria
using troponin-Tand creatine kinase-muscle brain isoenzyme according to
the Appendix.
Clinical Management
The procedures were performed by 26 consultant surgeons and 36 con-
sultant anesthesiologists. Details of the surgical and anesthesiologic man-
agement are listed in the Appendix and Table 1.
Statistical Analysis
The sample size determination (80% power; P< .05) according to
the clinical results at Link€oping University Hospital from 1995 to
2000 suggested that 2214 patients would be required with regard to
the primary endpoint, assuming a 30% reduction of events occurring
in 12% of untreated patients. An interim analysis was planned to oc-
cur after the inclusion of 800 patients. The trial was terminated after
the interim analysis because the prespecified stopping criteria per
protocol had been fulfilled (see the Appendix). The specific reasons
included no absolute difference in favor of glutamate with regard tordiovascular Surgery c Volume 144, Number 4 923
TABLE 1. Preoperative and intraoperative data for whole study
population
Variable
Placebo
(n ¼ 433)
Glutamate
(n ¼ 428)
Age (y) 68  9 68  9
Female gender 18.9% (82) 17.5% (75)
BMI (kg/m2) 27  4 27  4
euroSCORE* 5.0  2.8 5.3  2.8
Plasma creatinine (mmol/L) 97  29 98  27
COPD 5.4% (23) 7.6% (33)
Hypertension 59.8% (259) 56.4% (241)
Diabetes 25.4% (110) 23.9% (102)
Cerebrovascular disease 8.1% (35) 8.5% (36)
Extracardiac arterial disease 9.3% (40) 13.9% (59)
Braunwald class
NSTEMI 16.9% (73) 14.3% (61)
IB 10.8% (47) 12.9% (55)
IC 6.0% (26) 8.4% (36)
IIB 12.2% (53) 10.0% (43)
IIC 29.1% (126) 31.5% (135)
IIIB 11.1% (48) 9.1% (39)
IIIC 13.9% (60) 13.6% (58)
STEMI 0.0% (0) 0.2% (1)
CCS class
Unassessable 29.6% (128) 26.9% (115)
III 13.6% (59) 17.3% (74)
IV 55.9% (242) 54.4% (233)
Angina at rest<48 h preoperatively 23.6% (102) 19.2% (82)
Three-vessel disease 78.9% (342) 77.5% (332)
Left main stem stenosis 35.2% (152) 42.6% (182)
Recent myocardial infarction
0-24 h 1.2% (5) 0.2% (1)
1-7 d 22.6% (98) 24.4% (104)
8-21 d 37.2% (161) 40.7% (174)
Intravenous nitroglycerine preoperatively 8.5% (37) 8.9% (38)
ST-segment depression>1 mm in ORy 6.0% (26) 5.3% (23)
LV dysfunction
Moderate 14.1% (61) 14.8% (63)
Severe 5.1% (22) 3.7% (16)
Emergency procedure 5.5% (24) 4.2% (18)
Other operation than isolated CABG 4.6% (20) 3.7% (16)
Concomitant aortic valve procedure 2.1% (9) 1.4% (6)
Concomitant mitral valve procedure 2.1% (9) 1.4% (6)
Other concomitant procedure 0.4% (2) 0.9% (4)
OPCAB 2.1% (9) 3.5% (15)
Cold crystalloid cardioplegia 36.3% (157) 35.0% (150)
Cold blood cardioplegia 63.7% (276) 65.0% (278)
CPB time (min) 83  30 84  31
Aortic crossclamp time (min) 54  22 53  21
Use of LITA 95.8% (415) 95.3% (408)
Bypass (n) 3.8  1.2 3.8  1.2
Data presented as mean  standard deviation or proportions with numbers in paren-
theses. BMI, Body mass index; CABG, coronary artery bypass grafting; CCS, Cana-
dian Cardiovascular Society; COPD, chronic obstructive pulmonary disease; CPB,
cardiopulmonary bypass; euroSCORE, European System for Cardiac Operative
Risk Evaluation; LITA, left internal thoracic artery; LV, left ventricular (dysfunction
according to echocardiographic findings); NSTEMI, non–ST-segment elevation myo-
cardial infarction; OR, operating room; OPCAB, off-pump coronary artery bypass;
STEMI, ST-segment elevation myocardial infarction. *Additive euroSCORE.
yElectrocardiographic changes in operating room before institution of CPB.
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P
Mthe primary endpoint and no statistically significant differences
regarding the markers of myocardial injury or renal function in favor
of glutamate at the interim analysis.
Two-sided significance tests with Fisher’s exact test for categorical data
and Student’s t-test or the Mann-Whitney U test for continuous variables,
as appropriate, were used for the comparisons between the study groups.
The results are presented as percentages, the mean  standard deviation,
or median and interquartile range. The multivariate analysis and relative
risk calculations are described and presented in the Appendix (Tables E1
and E2). Adjustment for multiple testing was not performed. Statistical
analyses were performed using computerized statistical packages
(Statistica, version 9.1, StatSoft, Tulsa, Okla, and SPSS Statistics,
version 18, SPSS, Chicago, Ill).
Ethical Review
After the patients providedwritten informed consent, they were enrolled
in the study. The study was performed according to the Helsinki Declara-
tion of Human Rights and was approved by the Swedish Medical Products
Agency (151:2003/70403) and the Regional Ethical Review Board in Link-
€oping (M76-05).RESULTS
During the study period, 2087 patients underwent surgery
for acute coronary syndrome. Of these, 1064 were assessed
for eligibility, 865 were randomized, and 861 were included
in the study (Figure 1).
Four patients were excluded intraoperatively because of
intraoperative findings or events that overshadowed the
originally planned operation. Of the 4 patients, 2 were in
the glutamate group because of replacement of the ascend-
ing aorta and 2 were in the control group because of massive
air embolism from the pump and protracted extraordinary
bleeding complications. The data of the patients not in-
cluded in the present study who underwent surgery for acute
coronary syndrome during the study period are presented in
the Appendix (Tables E3 and E4).
The baseline data for the whole study population
(n ¼ 861) are listed in Table 1. The groups were evenly dis-
tributed, with the exception of significantly more patients
with extracardiac arterial disease (13.9% vs 9.3%;
P ¼ .04) and left main stenosis (42.6% vs 35.2%;
P ¼ .03) in the glutamate group.
The primary and secondary endpoints for thewhole study
population are listed in Table 2. The incidence of the com-
posite primary endpoint was 7.3% in the glutamate group
and 5.8% in the control group. The 30-day all-cause mortal-
ity was 0.9% in the glutamate group and 1.2% in the con-
trol group. None of these differences were statistically
significant.
A trend was seen in the secondary endpoints toward
fewer patients in the glutamate group requiring an intra-
aortic balloon pump on admission to the ICU (0% vs
1.2%; P ¼ .06) and fewer patients who were hemodynam-
ically unstable at surgery completion despite inotropic
drugs or the need for an intra-aortic balloon pump (0.3%
vs 1.8%; P ¼ .07).ery c October 2012
2087 patients underwent coronary surgery 
for acute coronary syndrome between 
October 4, 2005, and November 12, 2009 
1064 patients were assessed for eligibility 
865 underwent randomization 
Allocated to Glutamate infusion n=430 Allocated to Saline infusion n=435 
   Follow-up n=428 
   Lost to follow-up n=0 
Analyzed n=428 
Excluded from analysis n=0 
Analyzed n=433 
Excluded from analysis n=0 
 ALLOCATION 
FOLLOW-UP 
ANALYSIS
ENROLLMENT
58 met exclusion criteria 
98 declined participation 
30 participated in other trial 
13 other reasons
Excluded due to intraoperative 
exclusioncriteria n=2 
Excluded due to intraoperative 
exclusion criteria n=2 
   Follow-up n=433 
   Lost to follow-up n=0 
Received allocated intervention n=428 Received allocated intervention n=433 
FIGURE 1. Consort flow chart.
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MThe ICU stay or ventilator duration did not differ between
the groups; however, the patients with left ventricular failure
at weaning from CPB had a significantly shorter median
ICU stay (median, 25 hours; range, 18-57; vs 92 hours; range,
41-139;P¼ .02) and ventilator treatment (median, 5.0 hours;
range, 3.3-8.0; vsmedian, 7.4 hours; range, 5.8-49;P¼ .02) if
they had received glutamate infusion (Figure E1). In the co-
hort with left ventricular failure at weaning from CPB, the
postoperative lactate level measured 5 minutes after prot-
amine administrationwas significantly lower in the glutamate
group (1.7  0.5 vs 2.5  1.0 mmol/L; P ¼ .004).
The in-hospital or 30-day cardiac mortality was 0.2% in
the glutamate group and 0.9% the control group (P ¼ .37).
No significant differences were found regarding the inci-
dence of postoperative stroke.The Journal of Thoracic and CaSubgroup Analysis of Patients With Canadian
Cardiovascular Society Class IVAngina Undergoing
Isolated CABG
The baseline data for patients with Canadian Cardiovas-
cular Society (CCS) class IV angina undergoing isolated
CABG (n ¼ 458) are listed in Table 3. The groups were
evenly distributed, with the exception of significantly
more patients with left main stenosis (44.4% vs 34.3%;
P¼ .03) in the glutamate group. The primary and secondary
endpoints are listed in Table 4.
The incidence of the composite primary endpoint was
7.6% in the glutamate group and 7.8% in the control group.
The 30-day mortality was 0.9% in the glutamate group and
1.3% in the control group. None of these differences were
statistically significant.rdiovascular Surgery c Volume 144, Number 4 925
TABLE 2. Primary and secondary endpoints for whole study
population
Endpoint
Placebo
(n ¼ 433)
Glutamate
(n ¼ 428)
P
value
Primary 25 (5.8%) 31 (7.3%) .41
LV failure at weaning from
CPB
18 (4.2%) 20 (4.7%) .74
Perioperative myocardial
infarction
6 (1.4%) 11 (2.6%) .23
30-d Mortality 5 (1.2%) 4 (0.9%) 1.0
Secondary
Inotropes at weaning 53 (12.3%) 59 (13.8%) .54
Epinephrine 21 (4.9%) 19 (4.5%) .78
Milrinone 43 (10.0%) 40 (9.4%) .78
Other 9 (2.1%) 13 (3.0%) .37
SvO2 at weaning (%) 72.2  7.3 72.0  7.6 .69
SAP at weaning (mm Hg) 85  17 85  18 .93
a-Lactate mmol/L 5 min
after protamine
1.7  0.6 1.6  0.6 .07
Hemodynamic state at
surgery completion*
Stable without inotropes 310 (77.4%) 302 (78.5%) .73
Stable with inotropes 78 (19.8%) 87 (22.3%) .38
Unstable with inotropes/
IABP
7 (1.8%) 1 (0.3%) .07
Inotropes on admission
to ICU
58 (13.4%) 70 (16.4%) .25
Epinephrine 31 (7.2%) 36 (8.4%) .49
Milrinone 29 (6.7%) 31 (7.2%) .75
Other 7 (1.7%) 15 (3.5%) .78
IABP on admission to ICU 5 (1.2%) 0 (0%) .06
Late postoperative
circulatory failure
Cardiac 8 (1.8%) 10 (2.3%) .64
Noncardiac 15 (3.5%) 7 (1.7%) .13
Severe circulatory failure 18 (4.2%) 10 (2.3%) .18
Primary cardiac 15 (3.5%) 8 (1.9%) .20
CK-MB (mg/L) day 1
postoperatively
14 (10-23) 14 (10-23) .81
Troponin-T (mg/L) day 3-4
postoperatively
0.24 (0.13-0.52) 0.27 (0.16-0.57) .07
Plasma cystatin C (mg/L)
day 3-4 postoperatively
1.3  0.5 1.3  0.5 .21
Peak plasma creatinine
(mmol/L)
106  50 106  50 .86
Dialysis postoperatively 6 (1.4%) 2 (0.5%) .29
ICU duration (h) 21 (17-23) 21 (17-23) .65
Ventilator duration (h) 4.5 (3.1-6.8) 4.5 (3.0-6.5) .39
Postoperative atrial
fibrillation
152 (35.2%) 147 (34.4%) .83
Reoperation for bleeding/
tamponade
21 (4.8%) 22 (5.1%) .88
(Continued)
TABLE 2. Continued
Endpoint
Placebo
(n ¼ 433)
Glutamate
(n ¼ 428)
P
value
Stroke within 24 h
postoperatively
6 (1.4%) 4 (0.9%) .75
Stroke during hospital stay 6 (1.4%) 8 (1.9%) .60
Hospital mortality 6 (1.4%) 4 (0.9%) .75
Cardiac mortality
(in-hospital or 30-d)
4 (0.9%) 1 (0.2%) .37
Data presented as median with interquartile range in parentheses, mean  standard
deviation, or numbers with percentages in parentheses. CK-MB, Creatine kinase-
muscle brain isoenzyme; CPB, cardiopulmonary bypass; IABP, intra-aortic balloon
pump; ICU, intensive care unit; LV, left ventricular; SAP, systolic arterial pressure;
SvO2, mixed venous oxygen saturation. *Data available from 2 largest participating
centers.
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MRegarding the secondary endpoints, significantly fewer
patients in the glutamate group developed severe circulatory
failure (1.3% vs 6.9%; P ¼ .004).926 The Journal of Thoracic and Cardiovascular SurgIn the multivariate analysis (Table E1), glutamate infu-
sion was associated with a reduced risk of developing se-
vere circulatory failure (odds ratio, 0.2; 95% confidence
interval, 0.04-0.72; P ¼ .02). The addition of postoperative
bleeding or tamponade, the most common causes of late cir-
culatory failure of noncardiac origin, had no effect on the
final model. Intravenous glutamate infusion also remained
significantly associated with a reduced risk of developing
severe circulatory failure if the final model was adjusted
for the European System for Cardiac Operative Risk
Evaluation.
In CCS class IV patients, the postoperative lactate level
measured 5 minutes after protamine administration was sig-
nificantly lower in the glutamate group (1.6  0.5 vs 1.8 
0.6 mmol/L; P ¼ .006).
Other Subgroups
No statistically significant difference regarding the pri-
mary endpoint was found in the prespecified subgroups.
The effect of glutamate on the risk of developing severe cir-
culatory failure postoperatively in other risk groups was cal-
culated as the relative risk (Table E2). A relative risk
reduction exceeding 50% was seen in most categories un-
dergoing isolated CABG, with the exception of patients
with diabetes and those with a low event rate having
NSTEMI only without a history of angina.
Adverse Events
The adverse events are presented in Table E5. The inci-
dence of serious or nonserious adverse events did not differ
significantly between the study groups.
DISCUSSION
No significant between-group differences were found re-
garding the composite primary endpoint or markers for
myocardial injury or postoperative renal function. The latter
finding implied that the prespecified stopping criteria
were fulfilled at the interim analysis; hence, the study
was terminated. Subsequent analysis revealed significantery c October 2012
TABLE 3. Preoperative and intraoperative data for patients with CCS
class IV angina undergoing isolated CABG
Variable
Placebo
(n ¼ 233)
Glutamate
(n ¼ 225)
Age (y) 68  9 68  9
Female gender 19.7% (46) 17.3% (39)
BMI (kg/m2) 27  4 27  4
euroSCORE* 5.2  3.0 5.4  2.9
Plasma creatinine (mmol/L) 101  35 101  26
COPD 5.6% (13) 9.0% (20)
Hypertension 60.6% (141) 57.7% (130)
Diabetes 27.0% (63) 23.6% (53)
Cerebrovascular disease 8.6% (20) 8.9% (20)
Extracardiac arterial disease 10.7% (25) 14.5% (33)
Braunwald class
NSTEMI 4.7% (11) 3.1% (7)
IB 4.7% (11) 4.9% (11)
IC 2.1% (5) 3.1% (7)
IIB 13.3% (31) 12.4% (28)
IIC 33.0% (77) 37.3% (84)
IIIB 17.2% (40) 16.9% (38)
IIIC 24.9% (58) 22.2% (50)
STEMI 0.0% (0) 0.0% (0)
Angina at rest<48 h preoperatively 38.2% (89) 31.2% (70)
Three-vessel disease 77.7% (181) 77.8% (175)
Left main stem stenosis 34.3% (80) 44.4% (100)
Recent myocardial infarction
0-24 h 1.7% (4) 0.4% (1)
1-7 d 19.3% (45) 21.3% (48)
8-21 d 37.8% (88) 41.3% (93)
Intravenous nitroglycerine preoperatively 13.7% (32) 13.3% (30)
ST-segment depression>1 mm in ORy 9.0% (21) 6.0% (14)
LV dysfunction
Moderate 15.0% (35) 13.3% (30)
Severe 6.0% (14) 4.9% (11)
Emergency procedure 9.0% (21) 5.3% (12)
OPCAB 3.0% (7) 3.1% (7)
Cold crystalloid cardioplegia 43.8% (102) 42.9% (97)
Cold blood cardioplegia 56.2% (131) 57.1% (128)
CPB time (min) 81  25 83  30
Aortic crossclamp time (min) 53  17 53  17
Use of LITA 97.4% (227) 96.0% (216)
Bypass (n) 3.8  1.2 3.8  1.2
Data presented as mean  standard deviation or proportions with numbers in paren-
theses. BMI, Body mass index; CABG, coronary artery bypass grafting; CCS, Cana-
dian Cardiovascular Society; COPD, chronic obstructive pulmonary disease; CPB,
cardiopulmonary bypass; euroSCORE, European System for Cardiac Operative
Risk Evaluation; LITA, left internal thoracic artery; LV, left ventricular (dysfunction
according to echocardiographic findings); NSTEMI, non–ST-segment elevation myo-
cardial infarction; OR, operating room; OPCAB, off-pump coronary artery bypass.
*Additive euroSCORE. yElectrocardiographic changes in operating room before in-
stitution of CPB.
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Mbetween-group differences in favor of the glutamate group
regarding the secondary endpoints related to hemodynamic
recovery.
Although the trial findings were negative, the secondary
outcomes and post hoc analyses suggested that additional
clinical evaluation of intravenous glutamate would beThe Journal of Thoracic and Cawarranted. The results were compatible with the hypothesis
that glutamate mitigates postoperative heart failure by en-
hancing myocardial recovery. The incidence of left ventric-
ular failure at weaning from CPB did not differ between the
groups; however, the post hoc analysis revealed that patients
with weaning problems treated with glutamate had substan-
tially shorter ICU stay and ventilator treatment (Figure E1).
In patients with more severe ischemia (CCS class IVangina)
undergoing isolated CABG, significantly fewer developed
severe circulatory failure in the glutamate group. Multivar-
iate analysis identified intravenous glutamate infusion as
the only variable associated with a reduced incidence of se-
vere circulatory failure. This effect with a relative risk re-
duction exceeding 50% was found in most risk groups
undergoing isolated CABG in the present trial with the ex-
ception of patients with diabetes and those with a low event
rate having NSTEMI only as the first manifestation of cor-
onary artery disease. The relative risk calculations should
be interpreted cautiously owing to the low event rate, but
they provide guidance for future studies (Table E2).
The arterial lactate levels differed during early reperfu-
sion and, although the difference overall was minor, it could
reflect clinically more significant differences detected in
sicker patients, such as those with left ventricular failure
at weaning from CPB.
Patients with acute coronary syndrome were chosen for
the present trial because they represented the largest risk
group in our practice. Almost 30% of the patients in our
study were unassessable regarding CCS class because of
NSTEMI with a brief or uncertain history of angina or
NSTEMI as the only manifestation of coronary artery dis-
ease. Patients requiring emergency surgery were not eligi-
ble because of ethical reasons, further contributing to the
lower than anticipated event rates. Thus, it is questionable
whether the cohort studied can be regarded as a high-risk
group. Originally, the trial was intended for patients with
unstable angina; thus, patients with CCS class IVangina un-
dergoing isolated CABG were analyzed separately to ad-
dress this issue. The multivariate analysis was added to
adjust for other risk factors associated with the development
of severe circulatory failure.
Intravenous glutamate infusion according to our protocol
could influence the postoperative outcome by 2 different
biochemical mechanisms. First, glutamate could improve
myocardial tolerance to ischemia by facilitating anaerobic
metabolism during ischemia.4,5,7 In the present study, no
clinical evidence for this mechanism was found.
The second mechanism by which glutamate could influ-
ence the postoperative outcome after coronary surgery is re-
lated to the anaplerotic role of glutamate. Owing to its role
in the malate–aspartate shuttle, glutamate contributes to re-
plenishment of the Krebs cycle intermediates lost during is-
chemia.5,7 The lack of effect in patients with diabetes could
be explained by recently demonstrated downregulation ofrdiovascular Surgery c Volume 144, Number 4 927
TABLE 4. Primary and secondary endpoints for patients with CCS
class IV angina undergoing isolated CABG
Endpoint
Placebo
(n ¼ 233)
Glutamate
(n ¼ 225)
P
value
Primary 18 (7.8%) 17 (7.6%) 1.0
LV failure at weaning from
CPB
12 (5.2%) 12 (5.3%) 1.0
Perioperative myocardial
infarction
5 (2.2%) 6 (2.7%) .77
30-d Mortality 3 (1.3%) 2 (0.9%) 1.0
Secondary
Inotropes at weaning 28 (12.0%) 25 (11.2%) .88
Epinephrine 16 (6.9%) 11 (4.9%) .43
Milrinone 24 (10.3%) 14 (6.3%) .13
Other 4 (1.7%) 6 (2.7%) .53
SvO2% at weaning 71.7  7.1 71.6  7.6 .82
SAP weaning (mm Hg) 83  16 83  18 .96
a-Lactate mmol/l 5 min
after protamine
1.8  0.6 1.6  0.5 .006
Hemodynamic state at
surgery completion*
Stable without inotropes 186 (80.9%) 174 (79.8%) .81
Stable with inotropes 39 (17.0%) 43 (19.7%) .47
Unstable with inotropes/
IABP
5 (2.2%) 1 (0.5%) .22
Inotropes on admission
to ICU
34 (14.6%) 31 (13.8%) .89
Epinephrine 22 (9.4%) 20 (8.9%) .87
Milrinone 17 (7.3%) 11 (4.9%) .33
Other 3 (1.3%) 6 (2.7%) .33
IABP on admission to ICU 5 (2.1%) 0 (0%) .06
Late postoperative
circulatory failure
Cardiac 7 (3.0%) 4 (1.8%) .54
Noncardiac 11 (4.7%) 3 (1.3%) .05
Severe circulatory failure 16 (6.9%) 3 (1.3%) .004
Primary cardiac 13 (5.6%) 3 (1.3%) .02
CK-MB (mg/L) day 1
postoperatively
15 (10-24) 14 (10-22) .73
Troponin-T (mg/L) day 3-4
postoperatively
0.26 (0.14-0.59) 0.26 (0.15-0.53) .62
Plasma cystatin C (mg/L)
day 3-4 postoperatively
1.3  0.5 1.3  0.5 .30
Peak plasma creatinine
(mmol/L)
112  60 109  50 .59
Dialysis postoperatively 6 (2.6%) 1 (0.4%) .12
ICU duration (h) 21 (17-24) 20 (17-23) .40
Ventilator duration (h) 4.4 (3.1-6.8) 4.3 (2.8-6.4) .27
Postoperative atrial
fibrillation
76 (32.6%) 81 (36.0%) .49
Reoperation for bleeding/
tamponade
15 (6.4%) 9 (4.0%) .30
(Continued)
TABLE 4. Continued
Endpoint
Placebo
(n ¼ 233)
Glutamate
(n ¼ 225)
P
value
Stroke within 24 h
postoperatively
2 (0.8%) 2 (0.9%) 1.0
Stroke during hospital stay 3 (1.3%) 3 (1.3%) 1.0
Hospital mortality 5 (2.1%) 3 (1.3%) .72
Cardiac mortality
(in-hospital or 30-d)
2 (0.9%) 1 (0.4%) 1.0
Data presented as median with the interquartile range in parentheses, mean  stan-
dard deviation, or numbers with percentages in parentheses. CK-MB, Creatine
kinase-muscle brain isoenzyme; CPB, cardiopulmonary bypass; IABP, intra-aortic
balloon pump; ICU, intensive care unit; LV, left ventricular; SAP, systolic arterial
pressure; SvO2, mixed venous oxygen saturation; CCS, Canadian Cardiovascular So-
ciety; CABG, coronary artery bypass grafting. *Data available from 2 largest partici-
pating centers.
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Mthe mitochondrial glutamate transporter EAAT1, which was
associated with increased intracellular glutamate levels and
impaired postischemic protection by glutamate in the928 The Journal of Thoracic and Cardiovascular Surgdiabetic rat heart.18 The validity of these observations for
humans has been supported by findings in atrial biopsies
from humans undergoing CABG, demonstrating mitochon-
drial dysfunction and a sharply decreased capacity to
glutamate-supported respiration in patients with diabetes
compared with those without diabetes.19
Although not a mechanistic study, the secondary out-
comes of the present trial were compatible with enhanced
postischemic myocardial recovery in nondiabetic patients
undergoing CABG for unstable angina. This is in agreement
with the results of previous studies, suggesting that intrave-
nous glutamate infusion enhances recovery of myocardial
metabolism and function after ischemia.8,9,20 Promoting
recovery represents a different and more appealing
concept than the use of inotropic drugs that increase
oxygen expenditure, regardless of the state of myocardial
recovery. This could explain the encouraging clinical
outcomes previously reported with metabolic
interventions.10,11
Certain study limitations deserve comment. The study
was prematurely terminated because the prespecified stop-
ping criteria had been fulfilled; thus, most prespecified sub-
groups were too small for meaningful analysis. In
retrospect, we found that the inclusion of off-pump proce-
dures and operations with concomitant procedures was ill-
advised, because they added heterogeneity to the trial.
This reduced its power because many of the problems en-
countered were related to surgical technical issues and post-
operative bleeding. However, the various uses of
cardioplegia had no bearing on the outcomes of the trial
and did not influence the multivariate analysis with regard
to severe circulatory failure. The criteria used for postoper-
ative heart failure are inevitably debatable. Although this
condition is a major cause of postoperative mortality, the
generally accepted criteria for this diagnosis are lacking.17
To address this issue, we based the criteria on variables
documented with regard to outcome and provided the
blinded Clinical Endpoints Committee with strict prespeci-
fied criteria to minimize bias from individual clinicalery c October 2012
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Mjudgement.11,17,21,22 In retrospect, the usefulness of the
endpoint of left ventricular failure at weaning from CPB
is debatable, because it became evident at the Clinical
Endpoint Committee meetings that preemptive use of
inotropes prevented detection in patients who later
developed severe circulatory failure. Also, the duration of
intravenous glutamate infusion from the release of aortic
crossclamping to weaning might have been too short to
influence this endpoint. The secondary endpoint of severe
circulatory failure discriminated mild short-lasting heart
failure at weaning from CPB from clinically significant
heart failure requiring substantial circulatory support and
leading to prolonged ICU stay or death. For exploratory
purposes, the patients with severe circulatory failure were
divided into those with primary cardiac failure and those
with heart failure precipitated by extracardiac events such
as tamponade or bleeding. The difference in favor of gluta-
mate was significant for primary cardiac failure; however,
a trend was also found for fewer patients in the glutamate
group having severe heart failure precipitated by extracar-
diac events in patients with CCS class IVangina undergoing
isolated CABG (Table 4). Although the secondary out-
comes and subgroup analyses were provisional, even
when prespecified, the results should be regarded in the con-
text of current evidence. The treatment of postoperative
heart failure is determined by expert opinion, and the
need for large studies to assess the optimal method to man-
age postoperative heart failure has been emphasized.23
From the results of the present trial and previous clinical ex-
perience, we will continue using glutamate infusion in our
practice as an additive or alternative treatment in patients
with anticipated or evident heart failure at weaning from
CPB. However, additional studies are needed before intra-
venous glutamate can be generally recommended for pro-
moting postischemic recovery of the heart in cardiac
surgery.
A concern with the use of glutamate is that it might act as
an excitotoxin under certain conditions and participate in
events leading to neurologic damage.14 Available data
have not demonstrated any increase in clinically evident
neurologic injury when glutamate enhanced cardioplegic
solutions or intravenous infusions have been used in clinical
practice.24,25 No evidence of subclinical neurologic injury
associated with intravenous glutamate infusion was found
in the S100 calcium binding protein B (S-100B) substudy
of the present trial, and the present results showed no
differences in the neurologic outcome.14 Thus, it appears
that intravenous glutamate infusions in the dosages used
can be safely administered to patients undergoing cardiac
surgery.
CONCLUSIONS
In the present investigator-initiated trial of 861 patients
with acute coronary syndrome undergoing CABG,The Journal of Thoracic and Caglutamate did not prevent perioperative myocardial infarc-
tion or heart failure at weaning from CPB. However, the
secondary outcomes and post hoc analyses are compatible
with a beneficial effect of glutamate on postischemic myo-
cardial recovery. Patients with problems weaning from CPB
had a substantially shorter ICU stay and ventilator treatment
if they had received an intravenous glutamate infusion. In
patients with more severe ischemia (CCS class IV angina),
significantly fewer patients developed severe circulatory
failure in the glutamate group. Intravenous glutamate infu-
sion could provide a novel and important method of promot-
ing myocardial recovery after ischemic injury; however,
additional studies are required to establish the clinical
usefulness.
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APPENDIX
The study (GLUTAmate for Metabolic Intervention in
Coronary Surgery [ClinicalTrials.gov Identifier:
NCT00489827]) was approved by the Swedish Medical
Products Agency (151:2003/70403) and the Regional Ethi-
cal Review Board in Link€oping (M76-05). Amendments
were accepted by the Swedish Medical Products Agency
2006-08-31, 2007-05-08, 2007-11-01, and 2007-11-19.
External randomization in variable block sizes was done
by Apoteket AB (Produktion & Laboratorier, Umea,
Sweden).
External monitoring of all key data and unblinding proce-
dures was done by an independent professional monitoring
team (Clinical Research Support, available from: http://
www.orebroll.se/crs).
The recording of adverse events was done according to
the Good Clinical Practice standard.
INTERVENTION
Glutamate Solution
The glutamate solution was a 500-mL 0.125 M solution
of L-glutamic acid with a pH of 6.0 and 280 mOsmol/kg
containing L-glutamic acid 9.2 g, NaCl 0.8 g, water, and
500 mL and NaOH in the amount needed.
The production of glutamate solution and quality control
was done by Apoteket AB (Produktion & Laboratorier).
INCLUSION CRITERIA
The inclusion criteria were coronary artery bypass sur-
gery for acute coronary syndrome. Patients were eligible
for inclusion regardless of whether the procedure was
done on pump or off pump or whether the patient had under-
gone a simultaneous valve procedure.
EXCLUSION CRITERIA
The exclusion criteria were informed consent not possi-
ble because of a critical condition or other reason, the pre-
operative use of inotropic drugs or mechanical circulatory
assistance, preoperative dialysis, redo procedure, an unex-
pected intraoperative finding or event that increased the
magnitude of the procedure to overshadow the originally
planned operation, age older than 85 years, body weight
greater than 125 kg, and food allergy known to have caused
flush, rash, or asthma.
Stopping Criteria
The safety aspects had priority as stopping criteria. The
following stopping criteria were prespecified. The study
would be terminated:
If the monitoring or interim analysis revealed an in-
creased rate of stroke or mortality, the study would
be terminated before statistical significance was
reached.
If unexpected serious adverse events were detected in the
glutamate group.
If clinical benefit regarding mortality (P < .05) was
reached for glutamate infusion at interim analysis.
If no statistically significant difference was found re-
garding markers of myocardial injury or renal func-
tion in favor of glutamate infusion at interim analysis.
If no absolute difference was found in the primary end-
point in favor of glutamate infusion at the interim
analysis.
PRESPECIFIED ENDPOINTS
Primary Endpoint
The primary endpoint was a composite of postoperative
mortality (30 days), perioperative myocardial infarction
and left ventricular heart failure in association with weaning
from cardiopulmonary bypassE1 or after completion of off-
pump coronary artery bypass surgery.
Perioperative myocardial infarction. The criteria were
based on sustained elevation of troponin-T because of find-
ings demonstrating that early substantial elevation of
troponin-T can occur without permanent myocardial in-
jury.E1 Electrocardiographic Q waves have been found un-
reliable for diagnosis of perioperative myocardial infarction
after cardiac surgery.E2,E3 Perioperative myocardial
infarction was therefore defined by the following criteria:
troponin-Tof 2.0 mg/L or greater on the third or fourth post-
operative day.
In patients with recent myocardial infarction preopera-
tively (<1 week) or in patients with preoperatively ele-
vated troponin-T levels at least 1 of the following was
required:
Troponin-T of 2.0 mg/L or more on the third or fourth
postoperative day and creatinine kinase-MB greater
than 50 mg/L on the first postoperative morning
Troponin-T of 2.0 mg/L or more on the third or fourth
postoperative day and an increase in troponin-T
greater than 1.5 mg/L compared with the preoperative
levels
Left ventricular failure at weaning from cardiopulmo-
nary bypass or after completion of off-pump surgery.
Patients were considered to have left ventricular failure at
weaning from cardiopulmonary bypass or after completion
of off-pump surgery if criteria 1 and 2, 1 and 3, or 1 and 4
were fulfilled.
1. Consensus reached by the Endpoints Committee that left
ventricular failure was evident at weaning from cardio-
pulmonary bypass from the available records and hemo-
dynamic data
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2. Cardiac index of 1.9 L/min/m2 body surface area or less
with systolic arterial blood pressure (SAP) less than 100
mm Hg
3. Mixed venous oxygen saturation (SvO2) criteria in rela-
tion to SAP as listed fulfilled at weaning from cardiopul-
monary bypass, 5 minutes after the main dose of
protamine sulphate, and on admission to the intensive
care unit (ICU) that could not be explained by shivering,
anemia, or hypovolemiaE4-E6: SvO2 less than 50%, SAP
less than 130 mm Hg; SvO2 less than 55%, SAP less
than 110 mm Hg; SvO2 less than 60%, SAP less than
90 mm Hg; and SvO2 less than 65%, SAP less than 70
mm Hg
4. Use of intra-aortic balloon pump or the need for at least
1 inotropic agent in the dosages listed in the subsection
‘‘Inotrope Dosages’’ remaining on admission to the
ICU
Secondary Endpoints
The secondary endpoints covered the postoperative he-
modynamic state, myocardial ischemia and injury, renal
function, and neurologic safety issues.
Hemodynamic state. The postoperative hemodynamic
state, use of inotropic drugs and mechanical circulatory
support, hemodynamic instability at surgery comple-
tion, incidence of severe circulatory failure, need for
prolonged ICU stay, cardiac mortality, and late
mortality.
Postoperative heart failure was categorized as heart fail-
ure evident at weaning from cardiopulmonary bypass or late
circulatory failure presenting after apparently uncompli-
cated weaning. Late circulatory failurewas classified as car-
diac or noncardiac in origin.
Myocardial ischemia and injury. ST-segment depres-
sion of 1 mV or greater or ST-segment elevation of 2
mV or greater in the operating room on the electrocar-
diogram before the institution of cardiopulmonary by-
pass, degree of myocardial injury (creatine kinase-MB
on postoperative day 1, troponin-T on postoperative
day 3 or 4).
Postoperative atrial fibrillation. Renal function was de-
termined by plasma creatinine and plasma cystatin C, the
need for dialysis, and the incidence of plasma creatinine el-
evation greater than 50% compared with the preoperative
level.
The neurologic safety issues included stroke less than 24
hours after surgery, stroke during hospitalization, computed
tomography scan of the brain in suspected cases, S100 cal-
cium binding protein B (S-100B) on postoperative day 3
(substudy).E7
Hemodynamic instability at surgery completion. Patients
were considered hemodynamically unstable at surgery
completion if the attending anesthesiologist had classified
them in the institutional database as hemodynamically un-
stable despite the use of inotropic drugs or if an intra-
aortic balloon pump was needed. This classification was
performed at the 2 major participating centers, accounting
for 788 patients of the 861 included in the trial.
Severe circulatory failure. Patients were considered to have
had severe circulatory failure if criteria 1, 2, and 3 or 2 and 4
were fulfilled.
1. ICU stay of 48 hours or longer.
2. Consensus reached by Endpoints Committee that heart
failure presenting at weaning from cardiopulmonary by-
pass or later had occurred. This was decision had to be
supported by Cardiac Index or SvO2 data identical to
those prespecified for the primary endpoint left ventric-
ular failure at weaning from CPB.
3. The use of an intra-aortic balloon pump or the need for at
least 1 inotropic agent in dosages listed 24 hours or more
after admission to the ICU.
4. Mortality.
Inotrope Dosages
The dosages of the inotropes required for the preceding
criteria were as follows:
Epinephrine 0.033 mg/kg of body weight per minute.
Milrinone 0.375 mg/kg of body weight per minute.
Dopamine 4 mg/kg of body weight per minute.
Dobutamine 4 mg/kg of body weight per minute.
Levosimendan, regardless of dose plus additional inotro-
pic treatment in dosages as listed.
DATA COLLECTION
The key study data were prospectively recorded in a case
report form. Preoperatively, the patients were classified
with regard to the Canadian Cardiovascular Society class
and Braunwald class. The occurrence of angina at rest
within 48 hours before surgery and the occurrence of ST-
segment depression of 1 mm or greater or ST-segment ele-
vation of 2 mm or greater from admission to the operating
room to the onset of cardiopulmonary bypass were re-
corded. Troponin-T was sampled immediately before
surgery and on the third postoperative day. Creatine
kinase-MB was sampled on the first postoperative day.
Left ventricular function was assessed by transesophageal
echocardiography before the surgical incision and in associ-
ation with weaning from cardiopulmonary bypass. The he-
modynamic variables (ie, mixed venous oxygen saturation,
arterial saturation, heart rate, systolic and diastolic arterial
pressure, diastolic pulmonary artery pressure, central ve-
nous pressure) were recorded at weaning from cardiopul-
monary bypass or after termination of the last graft for
off-pump surgery, 5 minutes after administration of
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protamine sulphate, and on admission to the ICU. The use
of inotropic drugs or mechanical circulatory assistance
was recorded. Arterial plasma lactate was measured 5
minutes after administration of protamine sulphate.
Plasma cystatin-C and plasma creatinine was sampled
on the third postoperative day. The greatest postoperative
plasma creatinine level was also registered. Computed to-
mography was performed in cases with suspected perma-
nent neurologic injury. The basic demographic,
intraoperative, and postoperative data were recorded pro-
spectively in an institutional database (Carath) used at all
participating centers.
ROUTINES FOR UNBLINDING
The Swedish Medical Products Agency requested me-
ticulous surveillance and unblinding in cases of computed
tomography-verified stroke within 24 hours of surgery,
mortality, and suspected unexpected serious adverse reac-
tions. Before unblinding was done, the case was reviewed
by the Clinical Endpoints Committee if suspected circula-
tory problems had occurred. Recording of adverse events
was done according to the Good Clinical Practice
standard.
CLINICAL MANAGEMENT
Clinical management was standardized and similar at
the 3 participating centers with minor differences con-
cerning the choice of anesthetic drugs. After an overnight
fast, the patients received b-blockers and calcium antag-
onists orally, but antihypertensive and antidiabetic agents
were withheld. The standard premedication consisted of
orally administered flunitrazepam 0.5 to 1.0 mg or diaze-
pam 5 to 10 mg and ketobemidone 0.1 to 0.2 mg/kg body
weight or morphine 0.1 to 0.2 mg/kg body weight. Anes-
thesia was induced with thiopentone (2-3 mg/kg body
weight) or propofol (2 mg/kg body weight) supplemented
by a bolus dose of fentanyl 3 to 5 mg/kg body weight.
Muscle relaxation was achieved with pancuronium 0.1
mg/kg body weight or rocuronium 0.6 mg/kg body
weight. Anesthesia was maintained with isoflurane, sevo-
flurane, or propofol supplemented with intermittent doses
of fentanyl.
Standard monitoring was used consisting of a 5-lead
echocardiogram, pulse oximetry, continuous arterial
blood pressure monitoring using a cannula in the radial ar-
tery, central venous pressure, and transesophageal echo-
cardiography. A surgical pulmonary artery catheter was
introduced in all patients.E4,E5
Standard surgical techniques were used. Amedian ster-
notomy was performed in all patients. The use of cardio-
pulmonary bypass, a single-clamp technique for aortic
crossclamping, the method of myocardial protection,
and off-pump surgery are presented in Table 1.
Postoperative sedation was achieved with propofol.
The postoperative analgesia regimen consisted of keto-
bemidone 7 to 15 mg/kg body weight administered in-
termittent intravenously and acetaminophen 1 g every
sixth hour.
Extubation was performed when the body temperature
reached a level greater than 37C, the hemodynamic values
were stable, including a mixed venous saturation greater
than 55%, the oxygen partial pressure was greater than 10
kPawith fraction of inspired oxygen 0.4 and partial pressure
of carbon dioxide was less than 6.5 kPa, with a respiratory
rate less than 30 per minute and drainage loss less than 100
mL/hr and declining.
INVESTIGATORS
The Sponsor and Principal Investigator was Rolf Svedje-
holm, MD, Department of Cardiothoracic Surgery, Link-
€oping University Hospital, Link€oping, Sweden.
The remaining investigators were as follows: Erik
Hakansson, MD, Jonas Holm, MD, and Farkas Vanky,
MD, Department of Cardiothoracic Anesthesiology, Link-
€oping University Hospital, Link€oping, Sweden; Marten Vi-
dlund, MD, €Orjan Friberg, MD, and Lena Sunnermalm,
MD, Department of Cardiothoracic Surgery and Anesthesi-
ology, €Orebro University Hospital, €Orebro, Sweden; and
S€oren Juhl-Andersen, MD, Department of Cardiothoracic
Anesthesiology, Blekinge Hospital, Karlskrona, Sweden
(deceased); Jan Olov Borg, MD, Department of Cardiotho-
racic Surgery, Blekinge Hospital, Karlskrona, Sweden; Ra-
jiv Sharma, MD, Department of Cardiothoracic
Anesthesiology, Blekinge Hospital, Karlskrona, Sweden.
Clinical Endpoints Committee
The Clinical Endpoints Committee consisted of consul-
tants in cardiothoracic surgery and cardiothoracic anesthe-
siology from each of the participating centers. The
members of the committee were unaware of the treatment
assignment and prespecified criteria reported in the
Appendix were used to reach a consensus decision.
All patients with suspected postoperative heart failure
based on the SvO2 and other hemodynamic data, the use
of inotropic drugs or mechanical circulatory support, an
extended ICU stay, and circulatory problems reported
by the anesthesiologists or surgeons in the clinical data-
base were reviewed. The committee decided whether the
circulatory problems that met the prespecified criteria
had occurred, whether these circulatory problems were
severe, whether they were cardiac in origin, whether
they were evident at weaning from cardiopulmonary by-
pass or presented later in the postoperative course. The
committee also decided whether events leading to death
were cardiac in origin.
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FIGURE E1. Duration of (A) intensive care unit (ICU) stay and (B) ven-
tilator treatment in patients with left ventricular failure at weaning from
cardiopulmonary bypass in the glutamate group (n ¼ 20) or control group
(n ¼ 18). LV, Left ventricular; CPB, cardiopulmonary bypass.
TABLEE1. Multivariate analysis of risk factors for severe circulatory
failure in patients with CCS class IVangina undergoing isolatedCABG
Variable Adjusted OR 95% CI
P
value
Preoperative troponin-T level* 2.2 1.3-3.7 .004
Extracardiac vascular disease 6.5 1.8-23.6 .005
Severe systolic LV dysfunction 7.3 1.6-34.6 .01
Emergency procedure 5.1 1.4-18.9 .01
Intravenous glutamate infusion 0.2 0.04-0.72 .02
ST-segment depression 1 mV 3.8 1.0-14.4 .05
Variables were tested 1 at a time and those considered clinically relevant or with
P< .25 were tested with forward stepwise multiple logistic regression analysis.
Hosmer-Lemeshow goodness-of-fit statistics were calculated for the final model. Var-
iables: age, gender, weight, body mass index, diabetes, hypertension, chronic obstruc-
tive pulmonary disease, extracardiac arterial disease, cerebrovascular disease,
previous vascular surgery, preoperative hemoglobin, preoperative plasma creatinine,
preoperative troponin-T, triple-vessel disease, left main disease, previous myocardial
infarction, recent preoperative myocardial infarction, preoperative left ventricular
dysfunction, preoperative atrial fibrillation, Braunwald class, Canadian Cardiovascu-
lar Society class, angina at rest<48 hours from surgery, preoperative treatment with
intravenous nitrates, emergency procedure, ST-segment depression 1 mV on the
electrocardiogram in the operating room before institution of cardiopulmonary by-
pass, the use of crystalloid/blood cardioplegia, number of bypassed vessels, aortic
crossclamp time, and intravenous glutamate infusion. The influence of the additive
European System for Cardiac Operative Risk Evaluation and postoperative bleeding
or tamponade on the role of intravenous glutamate in the final model was also tested.
Hosmer-Lemeshow goodness-of-fit test chi square (df 5) ¼ 3.51, P ¼ .62. CI, Confi-
dence interval; LV, left ventricular;OR, odds ratio;CCS, Canadian Cardiovascular So-
ciety; CABG, coronary artery bypass grafting. *Per unit change.
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TABLE E2. Incidence of severe postoperative circulatory failure
Control/glutamate Control Glutamate RR 95% CI P value
Isolated CABG 413/411 16 (3.9%) 6 (1.5%) 0.38 0.15-0.95 .04
NSTEMI only 68/59 1 (1.5%) 1 (1.7%) 1.15 0.07-18 .92
Diabetes 108/98 4 (3.7%) 4 (4.1%) 1.10 0.28-4.3 .89
No diabetes 305/313 12 (3.9%) 2 (0.6%) 0.16 0.04-0.72 .02
CCS class IV 233/225 16 (6.9%) 3 (1.3%) 0.19 0.06-0.66 .008
Left main stenosis>50% 141/174 10 (7.1%) 1 (0.6%) 0.08 0.01-0.63 .02
Female gender 77/70 7 (8.5%) 2 (2.7%) 0.31 0.26-1.2 .14
euroSCORE  8 63/83 9 (14.3%) 4 (4.8%) 0.34 0.11-1.05 .06
Severe LV dysfunction 20/14 5 (25%) 1 (7.1%) 0.29 0.04-2.2 .23
Emergency* 13/14 4 (31%) 1 (7.1%) 0.23 0.03-1.6 .16
LV failure at weaning 14/18 8 (57%) 2 (11%) 0.19 0.05-0.78 .02
Data presented as relative risk 95% confidence interval of developing severe postoperative circulatory failure associated with glutamate treatment. Results were approximate,
given the small number of events (MedCalc Software, Mariakerke, Belgium). CABG, Coronary artery bypass grafting; CCS, Canadian Cardiovascular Society; CI, confidence
interval; euroSCORE, European System for Cardiac Operative Risk Evaluation; NSTEMI, non–ST-segment elevation myocardial infarction; LV, left ventricular; RR, relative risk.
*Emergency according to euroSCORE definition.
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TABLE E4. Outcome data for patients undergoing surgery for acute
coronary syndrome during study period but not included in
GLUTAMICS trial (n ¼ 780*)
Variable Value
30-d Mortalityy 4.0%
Inotropes in OR>30 min 34.2%
Hemodynamic state at surgery completion
Stable without inotropes 65.4%
Stable with inotropes 29.7%
Unstable with inotropes/IABP 4.3%
Creatine kinase-MB (mg/L) day 1 postoperatively
Median 15
Interquartile range 10-27
Troponin-T (mg/L) day 3-4 postoperatively
Median 0.4
Interquartile range 0.1-1.4
Peak plasma creatinine (mmol/L) 121  86
Dialysis postoperatively 2.2%
ICU duration (h)
Median 22
Interquartile range 18-37
Ventilator duration (h)
Median 5.3
Interquartile range 3.5-8.8
Postoperative atrial fibrillation 32.8%
Reoperation for bleeding/tamponade 5.8%
Reoperation sternal infection/dehiscense 1.7%
Stroke during hospital stay 2.3%
Data presented as median and interquartile range, mean standard deviation, or num-
bers with percentages in parentheses. GLUTAMICS, GLUTAmate for Metabolic In-
tervention in Coronary Surgery; IABP, intra-aortic balloon pump; ICU, intensive
care unit; OR, operating room. *Complete data available from 2 of participating cen-
ters (n ¼ 780). yData from all 3 participating centers (n ¼ 1222).
TABLE E3. Preoperative and intraoperative data for patients
surgically treated for acute coronary syndrome during the study
period but not included in the GLUTAMICS trial (n ¼ 780*)
Variable Value
Age (y) 68  9
Gender
Female 26.3%
Male 73.7%
Length (cm) 172  9
Weight (kg) 81  15
BMI (kg/m2) 27  4
euroSCOREy 6.1  3.9
Blood hemoglobin (g/L) 134  17
Plasma creatinine (mmol/L) 100  44
Active smokers 17.4%
COPD 7.1%
Hypertension 61.6%
Diabetes 28.1%
Cerebrovascular disease 8.6%
Extracardiac arterial disease 11.4%
Previous vascular surgery 4.6%
Carotid artery stenosis 3.2%
Multivessel disease
2-Vessel disease 18.4%
3-Vessel disease 75.7%
Left main stem stenosis 44.1%
Recent myocardial infarction
0-24 h 5.8%
1-7 d 21.4%
8-21 d 28.6%
Intravenous nitroglycerine preoperatively 11.5%
LV dysfunction
Moderate 15.2%
Severe 10.7%
Emergency procedure 11.5%
Operation other than isolated CABG 12.8%
OPCAB 5.1%
CPB time (min) 95  47
Aortic crossclamp time (min) 58  29
Single clamp 20.7%
Bypasses (n) 3.5  1.2
Data presented as mean standard deviation or percentages. BMI, Body mass index;
CPB, cardiopulmonary bypass; euroSCORE, European System for Cardiac Operative
Risk Evaluation; LITA, left internal thoracic artery; LV, left ventricular (dysfunction
according to echocardiography);OPCAB, off-pump coronary artery bypass;GLUTA-
MICS, GLUTAmate for Metabolic Intervention in Coronary Surgery; COPD, chronic
obstructive pulmonary disease; CABG, coronary artery bypass grafting. *Complete
data available from 2 of participating centers (n ¼ 780). yAdditive euroSCORE.
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TABLE E5. Adverse events in study population
Variable
Placebo
(n ¼ 433)
Glutamate
(n ¼ 428)
P
value
All adverse events 364 381
Patients with 1 serious adverse event 59 (13.6) 54 (12.6) .69
Serious adverse events 82 76
Circulatory 21 (4.8) 12 (2.8) .15
Perioperative myocardial infarction 6 (1.4) 11 (2.6) .23
Reoperation for bleeding 21 (4.8) 22 (5.1) .88
Respiratory 6 (1.4) 8 (1.9) .60
Gastrointestinal 2 (0.5) 1 (0.2) 1.0
Renal/urinary tract 9 (2.1) 8 (1.9) 1.0
Central nervous system 7 (1.6) 9 (2.1) .62
Infections 8 (1.8) 4 (0.9) .38
Other 2 (0.5) 1 (0.2) 1.0
Nonserious adverse events* 282 305
Circulatoryy 53 (13.4) 57 (14.5) .68
Respiratory 45 (11.4) 39 (9.9) .56
Gastrointestinal 6 (1.4) 5 (1.2) 1.0
Postoperative nausea and vomiting 114 (27.9) 139 (34.0) .06
Renal/urinary tract 18 (4.2) 22 (5.1) .52
Central nervous system 10 (2.5%) 5 (1.3%) .30
Infections 27 (6.8%) 33 (8.4%) .42
Skin 7 (1.8%) 3 (0.8%) .34
Other 2 (0.5%) 2 (0.5%) 1.0
Data presented as numbers with percentages in parentheses. *Complete data for non-
serious adverse events only available from 2 largest participating centers (n ¼ 788).
yPostoperative atrial fibrillation not included because it was presented in Table 2.
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